Crescent Biopharma (CBIO) Change in Account Payables (2013 - 2026)
Crescent Biopharma (CBIO) posted quarterly Change in Account Payables of $1.5 million for Q2 2026, up 257.64% year-over-year from $418298.2 in Q2 2025, and up 164.71% quarter-over-quarter from -$2.3 million in Q1 2026.
Crescent Biopharma (CBIO) Change in Account Payables (2013 - 2026) Analysis & Trends
Crescent Biopharma (CBIO) has reported Change in Account Payables for 14 consecutive years, with $1.5 million the latest figure, recorded in Q2 2026.
- In Q2 2026, Change in Account Payables rose 257.64% year-over-year to $1.5 million; the TTM figure through Jun 2026 stood at $1.7 million (up 37.0% YoY), while the FY2025 annual figure was $2.1 million, up 486.22% from the prior year.
- Change in Account Payables advanced to $1.5 million in Q2 2026 per CBIO's latest filing, from -$2.3 million in the prior quarter.
- Across five years, Change in Account Payables topped out at $1.6 million in Q3 2024 and bottomed at -$2.3 million in Q1 2026.
- Historically, Change in Account Payables has averaged $98730.4 across 5 years, with a median of $112533.0 in 2022.
- Annual changes were most pronounced in 2024 — Change in Account Payables surged 1667.01% — and 2025, when it slumped 586.1%.
- Crescent Biopharma's Change in Account Payables stood at $118066.0 in 2022, then surged by 355.87% to $538230.0 in 2023, then slumped by 80.12% to $107000.0 in 2024, then jumped by 857.01% to $1.0 million in 2025, then jumped by 46.09% to $1.5 million in 2026.
- Business Quant data shows CBIO's Change in Account Payables at $1.5 million in Q2 2026, -$2.3 million in Q1 2026, and $1.0 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Crescent Biopharma | 1.10 Bn | 933.02 Mn | - | 1.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.50 Mn |
| Jun 30, 2026 | 1.50 Mn |
| Mar 31, 2026 | -2.31 Mn |
| Mar 31, 2026 | -2.31 Mn |
| Dec 31, 2025 | 1.02 Mn |
| Dec 31, 2025 | 1.02 Mn |
| Sep 30, 2025 | 1.49 Mn |
| Sep 30, 2025 | 1.49 Mn |
| Jun 30, 2025 | -949,000.00 |
| Jun 30, 2025 | -949,000.00 |
| Mar 31, 2025 | 518,000.00 |
| Mar 31, 2025 | 518,000.00 |
| Dec 31, 2024 | 107,000.00 |
| Dec 31, 2024 | 107,000.00 |
| Sep 30, 2024 | 1.56 Mn |
| Sep 30, 2024 | 1.56 Mn |
| Jun 30, 2024 | 195,229.00 |
| Jun 30, 2024 | 195,229.00 |
| Mar 31, 2024 | -112,581.00 |
| Mar 31, 2024 | -112,581.00 |